Cullen Capital Management LLC Sells 18,483 Shares of Becton, Dickinson and Company $BDX

Cullen Capital Management LLC reduced its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 2.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 697,777 shares of the medical instruments supplier’s stock after selling 18,483 shares during the quarter. Cullen Capital Management LLC’s holdings in Becton, Dickinson and Company were worth $135,418,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of BDX. Imprint Wealth LLC acquired a new stake in shares of Becton, Dickinson and Company during the 3rd quarter worth about $25,000. Steph & Co. lifted its stake in shares of Becton, Dickinson and Company by 95.6% during the 4th quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock worth $26,000 after buying an additional 65 shares during the last quarter. WPG Advisers LLC lifted its stake in shares of Becton, Dickinson and Company by 64.2% during the 4th quarter. WPG Advisers LLC now owns 156 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 61 shares during the last quarter. Accredited Wealth Management LLC lifted its stake in shares of Becton, Dickinson and Company by 77.8% during the 3rd quarter. Accredited Wealth Management LLC now owns 160 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 70 shares during the last quarter. Finally, Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Becton, Dickinson and Company during the 4th quarter worth about $32,000. 86.97% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on BDX shares. TD Cowen cut their target price on shares of Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating for the company in a research note on Monday, May 4th. Argus cut their target price on shares of Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating for the company in a research note on Monday, March 23rd. Barclays boosted their price target on Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an “overweight” rating in a research note on Monday, May 11th. Wells Fargo & Company boosted their price target on Becton, Dickinson and Company from $157.00 to $161.00 and gave the company an “equal weight” rating in a research note on Friday, May 8th. Finally, BofA reduced their price target on Becton, Dickinson and Company from $177.00 to $170.00 in a research note on Friday. Seven equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $182.73.

Becton, Dickinson and Company Stock Performance

BDX opened at $146.13 on Friday. The business has a fifty day simple moving average of $150.00 and a 200 day simple moving average of $174.05. The company has a market capitalization of $40.27 billion, a PE ratio of 37.00, a price-to-earnings-growth ratio of 10.43 and a beta of 0.22. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $187.35. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.94 and a quick ratio of 0.55.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.13. The business had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.67 billion. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The firm’s quarterly revenue was up 5.2% on a year-over-year basis. During the same period in the previous year, the company posted $3.35 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Research analysts expect that Becton, Dickinson and Company will post 12.61 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Investors of record on Tuesday, June 9th will be paid a $1.05 dividend. The ex-dividend date is Tuesday, June 9th. This represents a $4.20 annualized dividend and a yield of 2.9%. Becton, Dickinson and Company’s payout ratio is 106.33%.

Insiders Place Their Bets

In other news, CEO Thomas E. Polen, Jr. sold 2,764 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $146.35, for a total transaction of $404,511.40. Following the completion of the sale, the chief executive officer directly owned 110,163 shares in the company, valued at approximately $16,122,355.05. This represents a 2.45% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of the company’s stock in a transaction on Wednesday, June 10th. The shares were sold at an average price of $151.48, for a total value of $166,628.00. Following the sale, the executive vice president owned 14,272 shares of the company’s stock, valued at approximately $2,161,922.56. The trade was a 7.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 4,013 shares of company stock valued at $593,434. Corporate insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.